e-learning
resources
Vienna 2012
Sunday, 02.09.2012
Instructive clinical aspects of thoracic oncology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A temporal effect of EGFR tyrosine kinase inhibitor in lymphoepithelioma-like carcinoma of lung
K. Chiu, K. Chiu, T.S. Chen (Taichung, Yilan, Taiwan)
Source:
Annual Congress 2012 - Instructive clinical aspects of thoracic oncology
Session:
Instructive clinical aspects of thoracic oncology
Session type:
Thematic Poster Session
Number:
1249
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Chiu, K. Chiu, T.S. Chen (Taichung, Yilan, Taiwan). A temporal effect of EGFR tyrosine kinase inhibitor in lymphoepithelioma-like carcinoma of lung. Eur Respir J 2012; 40: Suppl. 56, 1249
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
EGFR tyrosine kinase inhibitors
versus
chemotherapy in
EGFR
wild-type pre-treated advanced nonsmall cell lung cancer in daily practice
Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017
Year: 2017
RON tyrosine kinase mutations in brain metastases from lung cancer
Source: ERJ Open Res, 4 (1) 00083-2017; 10.1183/23120541.00083-2017
Year: 2018
The inhibitory effect of PI3k inhibitor and MEK inhibitor on malignant pleural mesothelioma cell growth
Source: Annual Congress 2009 - Pleural and mediastinal diseases
Year: 2009
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
Source: Eur Respir J 2012; 39: 366-372
Year: 2012
Lung adenocarcinoma patients of young age have lower
EGFR
mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
Source: ERJ Open Res, 3 (3) 00092-2016; 10.1183/23120541.00092-2016
Year: 2017
Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis
Source: Eur Respir J 2013; 41: 417-424
Year: 2013
Radiation/cisplatin/vinorelbine therapy increase p53 protein phosphorylated at serine 392 in recurrent primary squamous cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 17s
Year: 2001
Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Uncommon EGFR mutations of lung adenocarcinoma in one tertiary institution, Korea: clinical characteristics and treatment response to tyrosine kinase inhibitors
Source: International Congress 2018 – Lung cancer: from the bench to the bedside
Year: 2018
The prediction of risk factors of tyrosine kinase inhibitor-induced pneumonitis in non-small cell lung cancer
Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause
Year: 2020
Inhibition of phosphatidylinositol 3-kinase and mitogen-activated protein kinase kinase prevents malignant pleural mesothelioma cell growth
Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology
Year: 2010
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer
Source: Eur Respir J 2012; 39: 677-684
Year: 2012
Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells
Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer
Year: 2020
MEK5 promotes lung adenocarcinoma
Source: Eur Respir J, 53 (2) 1801327; 10.1183/13993003.01327-2018
Year: 2019
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up
Source: Eur Respir J 2009; 33: 436-440
Year: 2009
Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer
Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours
Year: 2015
Effect of PDGF receptor tyrosine kinase inhibitor AG1296 on bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2004 - Pulmonary fibrosis - new insights
Year: 2004
CREB signaling in KRAS-driven lung adenocarcinoma
Source: ERS Lung Science Conference 2017
Year: 2017
The predictive value of circulating tumor DNA dynamics in plasma of EGFR-mutation-positive NSCLC patients on first line tyrosine kinase inhibitors
Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept